Transforming Discovery & Translational Fibrosis Research into Disease Modifying IPF Therapeutics
The inaugural Idiopathic Pulmonary (IPF) Summit is the only event solely dedicated to transforming discovery & translational fibrosis research into disease modifying IPF therapeutics,
This unique IPF meeting is your opportunity to join the leading minds across biopharma and academia to reduce the expansive translational gap that exists in current IPF drug development.
The IPF Summit enabled attendees to share insights and network with the key players, including Bristol-Myers Squibb, Genentech, Patara Pharma Inc, Boehringer Ingelheim, Promedior and Fibrogen. Across 3 jam-packed days the brightest minds shared their insight and lessons learned to collectively enable the community to:
"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!” AstraZeneca - Previous Hanson Wade Life Sciences event attendee